Prof. Dr. Dolores Schendel, CEO of Medigene AG, commented: "Today's resolutions of the Annual General Meeting give Medigene the necessary leeway to efficiently pursue the company's operational goals and to be able to use strategic options quickly and flexibly. We thank our shareholders for their confidence and look forward to further implementing our goals. "
Agenda / Resolutions:
Item 1) Presentation of the financial statements 2017
Item 2) and 3) Discharge of the Executive Management Board members and the Supervisory Board members for the financial year 2017
Item 4) Election of Ernst & Young GmbH as auditors and group auditors
Item 5) Revocation of the Contingent Capital XVI & XXII
Item 6) and 7) Revocation of Authorized Capital and creation of new Authorized Capital of 40% and 10% of the share capital for the issue of new shares.
For the capital decisions under items 6, 7 and 9, the exclusion of subscription rights is possible under certain conditions, but this is limited to a maximum of 20% of the share capital (voluntary self-restriction).
Item 8) Reduction of the Contingent Capital 2016/II and creation of a new Contingent Capital 2018/I for the issue of option rights (stock option program for the Executive Board and employees)
Item 9) Revocation of Contingent Capital 2016/I and creation of a new Contingent Capital 2018/II for the issue of convertible or warrant bonds
Item 10) and 11) Increase of the number of Supervisory Board members and election of Dr. Frank Mathias, CEO of Rentschler SE, Laupheim, as a further member of the Supervisory Board
The approval rates of the Annual General Meeting for proposed resolutions were between 97.8% and 99.9%.
For more information, please follow the link: https://www.medigene.com/investors-media/annual-general-meeting/2018/
Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, TecDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development. For more information, please visit http://www.medigene.com
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.
Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01
In case you no longer wish to receive any information about Medigene, please inform us by e-mail (firstname.lastname@example.org). We will then delete your address from our distribution list. (end)
Lochhamer Straße 11
|contact person:||Medigene PR/IR|
|phone:||+49 89 2000 33 3301|
|stock exchanges:||regulated market in Frankfurt; free market in Dusseldorf, free market in Hamburg, free market in Hannover, free market in Munich, free market in Stuttgart; open market in Berlin, Tradegate|